Drug Patent Expirations in March 2013

Drug Patent Expirations for March 2013

Tradename Applicant Generic Name Patent Number Patent Expiration
THALOMID Celgene thalidomide 8,143,283 Mar 1, 2013
THALOMID Celgene thalidomide 7,723,361 Mar 1, 2013
THALOMID Celgene thalidomide 6,235,756 Mar 1, 2013
ZOMETA Novartis zoledronic acid 4,939,130*PED Mar 2, 2013
LUNESTA Sunovion Pharms Inc eszopiclone 6,864,257*PED Mar 2, 2013
RECLAST Novartis zoledronic acid 4,939,130*PED Mar 2, 2013
NATROBA Parapro Llc spinosad 5,496,931 Mar 5, 2013
FLO-PRED Taro prednisolone acetate 6,102,254 Mar 11, 2013
ABRAXANE Abraxis Bioscience paclitaxel 5,498,421 Mar 12, 2013
COMBIVENT RESPIMAT Boehringer Ingelheim albuterol sulfate; ipratropium bromide 5,497,944 Mar 12, 2013
RYBIX ODT Shionogi Inc tramadol hydrochloride 5,464,632 Mar 22, 2013
XOPENEX Sunovion levalbuterol hydrochloride 5,362,755 Mar 25, 2013
XOPENEX HFA Sunovion levalbuterol tartrate 5,362,755 Mar 25, 2013
SILENOR Somaxon doxepin hydrochloride 5,502,047 Mar 26, 2013
LOVAZA Smithkline Beecham omega-3-acid ethyl esters 5,502,077 Mar 26, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Comments are closed.